Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Non-Small Cell Lung Cancer”

218 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 218 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06537297
What this trial is testing

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 30
Early research (Phase 1)Ended earlyNCT03255083
What this trial is testing

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 13
Testing effectiveness (Phase 2)Ended earlyNCT02770014
What this trial is testing

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Who this might be right for
Epidermal Growth Factor ReceptorNon-Small Cell Lung Cancer
Dana-Farber Cancer Institute 43
Testing effectiveness (Phase 2)Looking for participantsNCT07742332
What this trial is testing

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Who this might be right for
EGFRNSCLC (Non-small Cell Lung Cancer)Locally Advanced Non-Small Cell Lung Cancer+2 more
Peng Zhang 160
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Large-scale testing (Phase 3)Not Yet RecruitingNCT06323148
What this trial is testing

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Who this might be right for
Lung CancerEGFR Gene MutationMinimal Residual Disease
Fudan University 226
Testing effectiveness (Phase 2)UnknownNCT03749213
What this trial is testing

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

Who this might be right for
EGF-R Positive Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 36
Testing effectiveness (Phase 2)UnknownNCT02771314
What this trial is testing

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07807722
What this trial is testing

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)EGFRNeoadjuvant Therapy
Hubei Cancer Hospital 29
Testing effectiveness (Phase 2)Study completedNCT02064491
What this trial is testing

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Finnish Lung Cancer Group 18
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Testing effectiveness (Phase 2)Looking for participantsNCT06106802
What this trial is testing

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Sehhoon Park 47
Not applicableUnknownNCT04575415
What this trial is testing

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 272
Testing effectiveness (Phase 2)UnknownNCT05244213
What this trial is testing

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

Who this might be right for
Non-small Cell Lung CancerEGFR Activating Mutation
Guangdong Provincial People's Hospital 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04545710
What this trial is testing

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
Lung Cancer
University of California, San Diego 18
Testing effectiveness (Phase 2)Study completedNCT02879994
What this trial is testing

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Stage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center 11
Testing effectiveness (Phase 2)Ended earlyNCT04971187
What this trial is testing

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT01866410
What this trial is testing

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Looking for participantsNCT05394831
What this trial is testing

Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Who this might be right for
EGFR Mutant Advanced Non-small Cell Lung Cancer
J Ints Bio 150
Next Page